Idecabtagene Vicleucel in Patients With Transplant-Ineligible High-Risk Multiple Myeloma
July 14, 2025 • CAR-T Content Hub
Xavier Leleu, MD, PhD, Poitiers University Hospital, Poitiers, France, discusses findings from one arm of the Phase 2 KarMMA-2 trial that was designed to investigate idecabtagene vicleucel in patients with transplant-ineligible high-risk multiple myeloma. The overall response rate was more than 90%, and the complete response rate was over 60%, with most of these patients achieving measurable residual disease negativity. Median progression-free survival was not yet reached at 21 months, and the 2-year expected progression-free survival was 63%. Idecabtagene vicleucel had a favorable safety profile.
